Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-11-17Clinical Trial Update: Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors [NA]
The document reports a completed University of North Carolina clinical trial studying survivorship and psychological outcomes in bone marrow…
-
CLINICAL_TRIALS trial_result · 2017-11-14Clinical Trial Update: Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. [Phase 1]
This update reports the completion of a Phase 1 trial evaluating lenalidomide in acute myeloid leukemia, acute lymphoblastic leukemia, and c…
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma [Phase 1]
Phase 1 clinical evaluation of nelarabine in Japanese patients with acute lymphoblastic leukemia and lymphoblastic lymphoma has been complet…
-
FDA approval · 2017-11-09FDA Approved: CYTARABINE — Original Application (Meitheal Pharmaceuticals Inc.)
The FDA approved the original abbreviated new drug application for Cytarabine from Meitheal Pharmaceuticals, enabling the generic injectable…
-
CLINICAL_TRIALS trial_result · 2017-11-08Clinical Trial Update: T-cell Depleted Alternative Donor Transplantation [Phase 2]
Phase 2 clinical trial of T-cell depleted alternative donor transplantation for acute leukemias and related conditions was terminated with r…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2017-11-08Clinical Trial Update: Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia
A clinical trial update examines the effect of a chemotherapy regimen combined with a tyrosinase inhibitor on reactivation of CMV and EBV in…
-
FDA approval · 2017-11-06FDA Approved: CLOFARABINE — Original Application (Amneal Pharmaceuticals LLC)
FDA approves a generic version of CLOFARABINE (Amneal) under an Original Application for the treatment of acute lymphoblastic leukemia.
-
FDA approval · 2017-11-06FDA Approved: CLOFARABINE — Original Application (Dr.Reddy's Laboratories Inc)
FDA approved Dr. Reddy's Laboratories' generic clofarabine (Clofarabine) under ANDA205375.
-
FDA approval · 2017-11-06FDA Approved: CLOFARABINE — Original Application (Mylan Institutional LLC)
FDA approves a generic original application for Clofarabine (Clofarabine) by Mylan Institutional LLC.
-
FDA approval · 2017-11-03FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for doxorubicin hydrochloride from BluePoint Laboratories, adding a new approved generic version of …
-
CLINICAL_TRIALS trial_result · 2017-10-12Clinical Trial Update: Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia [Phase 2, Phase 3]
A Phase 2/3 trial evaluating intensified conditioning with high-dose etoposide for adults undergoing allogeneic hematopoietic stem cell tran…
-
CLINICAL_TRIALS trial_result · 2017-10-02Clinical Trial Update: CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial update for CAT-8015 in children and young adults with acute lymphoblastic leukemia or non-Hodgkin's lymphoma; study completed …
-
FDA approval · 2017-09-29FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approves a supplemental NDA for GLEEVEC (imatinib mesylate) filed by Novartis Pharmaceuticals Corporation, resulting in changes to the p…
-
CLINICAL_TRIALS trial_result · 2017-09-27Clinical Trial Update: Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A completed phase 1/2 trial evaluating safety and efficacy of Astarabine in acute myeloid leukemia and acute lymphoblastic leukemia.
-
CLINICAL_TRIALS trial_result · 2017-09-15Clinical Trial Update: Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT [Phase 2]
Phase 2 trial evaluating abatacept-based immunosuppression to prevent acute graft-versus-host disease during unrelated donor hematopoietic c…
-
CLINICAL_TRIALS trial_result · 2017-08-30Clinical Trial Update: Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome [Phase 1]
Phase 1 trial evaluating donor peripheral blood stem cell transplantation in combination with pretargeted radioimmunotherapy for patients wi…
-
CLINICAL_TRIALS research · 2017-08-29Clinical Trial Update: New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia
A clinical trial update from Assiut University investigates new markers for detecting minimal residual disease in acute lymphoblastic leukem…
-
CLINICAL_TRIALS trial_result · 2017-08-22Clinical Trial Update: PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias [Phase 1]
Phase 1 pharmacokinetic study of oral and intravenous clofarabine in high-risk myelodysplastic syndrome and acute leukemias; the trial has c…
-
CLINICAL_TRIALS trial_result · 2017-08-22Clinical Trial Update: Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib [Phase 2]
Phase 2 trial assessing fludarabine phosphate with total-body irradiation followed by donor peripheral blood stem cell transplant in adults …
-
FDA approval · 2017-08-17FDA Approved: BESPONSA — Original Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved BESPONSA (inotuzumab ozogamicin) under an original application for adults with relapsed or refractory CD22-positive B-cell prec…
-
FDA approval · 2017-08-10FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for dasatinib submitted by Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2017-08-10Clinical Trial Update: Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant [Phase 2]
Phase 2 clinical trial update assessing safety and tolerability of HSC835 in patients with hematological malignancies undergoing single umbi…
-
CLINICAL_TRIALS trial_result · 2017-08-09Clinical Trial Update: Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies [Phase 2]
This Phase 2 randomized trial comparing haplo cord blood transplantation versus double umbilical cord blood transplantation for hematologic …
-
CLINICAL_TRIALS trial_result · 2017-08-09Clinical Trial Update: Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) [Phase 3]
Phase 3 trial comparing blinatumomab to standard chemotherapy in relapsed or refractory B-precursor acute lymphoblastic leukemia; the study …
-
CLINICAL_TRIALS trial_result · 2017-08-08Clinical Trial Update: Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase 1/2 trial of entinostat plus imatinib mesylate in relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia; t…